Krystal Biotech, Inc.KRYSEarnings & Financial Report
Krystal Biotech, Inc. is a clinical-stage biotechnology company specializing in the research, development and commercialization of novel gene therapies for rare, serious dermatological diseases with high unmet medical needs. It primarily serves patients across North America and Europe, focusing on monogenic skin disorders that lack effective standard treatment options.
KRYS Q4 FY2025 Key Financial Metrics
Revenue
$107.1M
Gross Profit
N/A
Operating Profit
$44.4M
Net Profit
$51.4M
Gross Margin
N/A
Operating Margin
41.5%
Net Margin
48.0%
YoY Growth
17.5%
EPS
$1.69
Krystal Biotech, Inc. Q4 FY2025 Financial Summary
Krystal Biotech, Inc. reported revenue of $107.1M (up 17.5% YoY) for Q4 FY2025, with a net profit of $51.4M (up 13.0% YoY) (48.0% margin).
Key Financial Metrics
| Total Revenue | $107.1M |
|---|---|
| Net Profit | $51.4M |
| Gross Margin | N/A |
| Operating Margin | 41.5% |
| Report Period | Q4 FY2025 |
Krystal Biotech, Inc. Annual Revenue by Year
Krystal Biotech, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $389.1M).
Krystal Biotech, Inc. Quarterly Revenue & Net Profit History
Krystal Biotech, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $107.1M | +17.5% | $51.4M | 48.0% |
| Q3 FY2025 | $97.8M | +16.6% | $79.4M | 81.2% |
| Q2 FY2025 | $96.0M | +36.6% | $38.3M | 39.9% |
| Q1 FY2025 | $88.2M | +94.9% | $35.7M | 40.5% |
| Q4 FY2024 | $91.1M | +116.3% | $45.5M | 49.9% |
| Q3 FY2024 | $83.8M | +879.9% | $27.2M | 32.4% |
| Q2 FY2024 | $70.3M | — | $15.6M | 22.2% |
| Q1 FY2024 | $45.3M | — | $932.0K | 2.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $45.3M | $70.3M | $83.8M | $91.1M | $88.2M | $96.0M | $97.8M | $107.1M |
| YoY Growth | N/A | N/A | 879.9% | 116.3% | 94.9% | 36.6% | 16.6% | 17.5% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $853.3M | $917.7M | $982.3M | $1.06B | $1.07B | $1.14B | $1.24B | $1.33B |
| Liabilities | $54.1M | $78.8M | $96.5M | $109.5M | $89.7M | $97.7M | $102.2M | $114.2M |
| Equity | $799.2M | $838.9M | $885.8M | $946.4M | $984.7M | $1.04B | $1.14B | $1.22B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $15.9M | $-4.2M | $58.9M | $52.8M | $31.0M | $52.7M | $39.7M | $77.5M |